American College of Rheumatology, Systemic Lupus Erythematosus

(Junvile).http://www.rheumatology.org/I-Am-A/Patient
Caregiver/Diseases-Conditions/Systemic-Lupus-Erythematosus-Juvenile
[diakses 23 Pebruari 2018].
Angelina, Maya. 2016. KARAKTERISTIK PENDERITA SYSTEMIC LUPUS
ERYTHEMATOSUS (SLE) YANG DIRAWAT INAP DI RSUP H.
ADAM MALIK MEDANTAHUN 2011-2015. Skripsi. Medan :
Universitas Sumatera Utara

Asih, Rizky Ayu Fandika. 2016. Hubungan Keparahan Penyakit, Aktivitas dan
Kualitas Tidur Terhadap Kelelahan Pasien Systemic Lupus Erythematosus.
Skripsi. Semarang : Universitas Negeri Semarang

Badan Pusat Statistik Sumatera Utara . 2017.

httpssumut.bps.go.idsubject12kependudukan.html#subjekViewTab3.
(diakses 26 Juli 2018).

Dharmeizar, 2003. Nefritis Lupus : Pendekatan Diagnostik dan

Penatalaksanaan. Jakarta : Perhimpunan Reumatologi Indonesia

Isbagio, H., Kasjmir, YI., Setyohadi, B., dan Suarjana, N., 2010. Lupus
Eritematosus Sistemik. Ilmu Penyakit Dalam Jilid III Edisi V. Jakarta :
InternalPublishing
Kanoko, Mpu., 2010. Patologi I (Umum). Jakarta : Sagung Seto
Kemenkes RI., 2017. Situasi Lupus di Indonesia. Jakarta: Kemenkes RI

Nasution, A.R, Sumariyono. 2015. Introduksi Reumatologi. Ilmu Penyakit Dalam

Jilid III Edisi VI. Jakarta : InternalPublishing
Ongkowijaya J.A, Sumartini Dewi, Nyoman Suarjana, Ratih Wulansari Manuaba, Ida
Ayu, Yoga I Kasjmir1, Kusworini Handono2, Linda Kurniaty Wijaya,
Laniyati Hamijoyo, Zuljasri Albar, Handono Kalim, Hermansyah, Nyoman
Kertia, Deddy Nur Wachid Achadiono. 2011. Rekomendasi
Perhimpunan Reumatologi Indonesia Untuk Diagnosis Dan
Pengelolaan Lupus Eritematosus Sistemik. Perhimpunan Reumatologi
Indonesia : Jakarta
Perhimpunan Reumatologi Indonesia., 2011. Diagnosis dan Pengelolaan Lupus
Eritematosus Sistemik. Jakarta: Perhimpunan Reumatologi Indonesia
Resmana, Fina Ranivira. 2018. Faktor Risiko Kejadian Penyakit Systemic
Lupus Erythematosus (SLE) Di RSUP DR. M. Djamil Padang Tahun
2017 . Skripsi. Padang : Universitas Andalas
Setiyohadi, Bambang. 2003. Penatalaksanaan Lupus Eritematosus Sistemik.
Jakarta : Ikatan Reumatologi Indonesia
Soedarto., 2014. Kamus Alergi dan Imunologi. Sagung Seto : Jakarta
Suarjana, N. 2015. Imunopatogenesis Lupus Eritematosus Sistemik. Ilmu
Penyakit Dalam Jilid III Edisi VI. Jakarta : InternalPublishing
Subowo. 2010. Imunologi Klinik. Bandung : Sagung Seto
Sumariyono, 2003. Spektrum Autoantibodi pada LES dan Hubungannya
dengan Gambaran Klinik. Jakarta : Perhimpuan Reumatologi Indonesia
 Suntoko, Bantar., 2015. Gambaran Klinik dan Diagnosis Lupus Eritematosis
Sistemik. Dalam Ilmu Penyakit Dalam Jilid III Edisi VI. Jakarta :
InternalPublishing

WHO, 2016. World Health Statistics 2016 Monitoring Health For The SDGs.
Prancis: WHO
WHO., 2017. World Health Statistics 2017 Monitoring Health For The SDGs.
Prancis: WHO

DAFTAR PUSTAKA

Bertsias, G., Cervera, R., Boumpas, D.T. 2012. Systemic Lupus Erythematosus :
Pathogenesis and Clinical Features, EULAR Textbook on Rheumatic Disease.
Switzerland. hlm. 476-505
Bertsias, G.K., Salmon, J.E., Boumpas, D.T. 2010. Therapeutic opportunities in systemic
lupus erythematosus: state of the art and prospects for the new decade. Ann Rheum
Dis. 69:1603–11
Bertsias, G.K, Ioannidis, J.P.A., Boletis, J., Bombardieri, S., Cervera, R., Dostal, C., et al.
2008. EULAR recommendations for the management of systemic lupus
erythematosus (SLE). Report of a Task Force of the European Standing Committee
for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis.
67:195–205
Buchori, Prihatini. 2006. Diagnosis Sepsis Menggunakan Procalcitonin (Sepsis Diagnosis by
Procalcitonin). Indonesian Journal of Clinical pathology and Medical
Laboratory.12(3):131-7
Buhaescu, I., Yood, R.A., Izzedine, H. 2010. Serum procalcitonin in systemic autoimmune
diseases – where are we now? Arthritis Rheum.40(2):176–83
Budak Y.U., Polat M., Huysal K. 2016. The use of platelet indices, plateletcrit, mean platelet
volume and platelet distribution width in emergency non traumatic abdominal surgery
: a systematic review. Biochemia Medica. 26(2):178-193
Chen Y, Du J, Lu X, Xu J.H. 2018. Platelet distribution width as a novel indicator of disease
activity in systemic lupus erythematosus. J Res Med Sci. 23: 48
Cervera, R., Espinosa, G., D’Cruz, D. 2009. Systemic Lupus Erythematosus: pathogenesis,
Clinical Manifestation and Diagnosis. In Eular Compendium on Rheumatic Diseases,
BMJ Publishing Group and European League Against Rheumatism 1st ed. hlm.257-
268
Chng, H.H. 2006. Management of Systemic Lupus Erythematosus in the Coming Decade:
Potentials and Challenges. APLAR Journal of Rheumatology. 9:419-424
Garcia GD, Delgado D.A, Pedraza IC, Almaguer O.D, Cruz I.M, Salgado D.B et al. 2016.
`Mean platelet volume is decreased in adults with active lupus disease,
Elsevier, 5 : 274
Gasparyan AY, Ayvazyan L, Mikhailidis D, Kitas G. 2011. Mean Platelet Volume: A
Link Between Thrombosis and Inflammation. 17: 47 – 58
Gheita TA, Abaza NM, Hammam N, Mohamed AAA, El-Gazzar II, Eissa AH. 2018.
Anti-dsDNA titre in female systemic lupus erythematosus patients: relation
to disease manifestations, damage and antiphospholipid antibodies. Lupus
.27(7):1081-1087.
Hahn, B.H. 2013. Systemic Lupus Erythematosus. Dalam : Fauci AS, editor. Harrison’s
Rheumatology 3rd Edition ; United State: McGraw-Hill Education. 68-83
Hartmann L.T, Alegretti A.P., Machado A.B.,Martins A.F., Chakr R.M., Gasparin A.A., et al.
2018. Assesment of Mean Platelet Volume in Patients with Systemic Lupus
Erythematosus. The Open Rheumatology Journal. 12: 129-138
Ho,W.L., Lan, J.L., Chen, D.Y., et al. 2009. Procalcitonin may be a potential biomarker for
distinguishing bacterial infection from disease activity in febrile patients with
systemic lupus erythematosus. Formos J Rheumatol. 23:52–58
HE Y, Shaoxian HU, 2020. Platelet distribution width level in Patients with Systemic Lupus
Erythematosus Associated Pulmonary Arterial Hypertension and its Diagnosic Value.
TLAR. 14-22
Islamoglu Z.G., Demirbas A. 2019. Mean Platelet Volume and platelet distribution witdh
levels in discoid lupus erythematosus patients: A case- control study. Journal of
Surgery and Medicine 3(8):561-563
Kasjmir, Y.I., Handono, K., Wijaya, L.K., et al. 2011. Diagnosis dan Pengelolaan Lupus
Eritematosus Sistemik, Rekomendasi Perhimpunan Reumatologi Indonesia. Hlm.4-18
Kasjmir, Y.I., Handono, K., Wijaya, L.K., et al. 2014. Diagnosis dan Pengelolaan Lupus
Eritematosus Sistemik. Dalam: Setiati S, editor. Buku Ajar Ilmu Penyakit Dalam. Jilid
III edisi VI. Jakarta: BP FKUI.
Khanna, S., Pal, H., Panday, R.M., Handa, R. 2004. The Relationship between Disease
Activity and Quality of Life in Systemic Lupus Erythematosus.Rheumatology
(Oxford).43(12):1536-40
Korniluk A, Lenkiewicz O, Kaminska J, Kemona H, Piekarska V, 2019 Mean Platelet
Volume (MPV): New Perspectives for an Old Marker in the Course and Prognosis of
Inflammatory Conditions .Hindawi Mediators Of Inflammation. 14(2): 132-137

Narayanan K, Marwaha V, Shanmuganandan K, Shankar S. 2010. Correlation between

Systemic Lupus Erythematosus Disease Activity Index, C3, C4 and Anti-dsDNA
Antibodies. Med J Armed Forces India. 66 (2): 102 - 107

Perdana. 2016. Korelas antara Mean Platelet Volume dengan MEX-SLEDAI dan D-Dimer
pada Pasien Lupus Eritematosus Sistemik.
Pusdatin. 2017. Situasi Lupus di Indonesia, Infodatin. Pusat Data dan Informasi Kementerian
Kesehatan. 1-2
Pervin S, Ferdoushi S, Hossain M, Al Joarder, Sultana T. 2016. Elevated mean platelet
volume is a marker of acute coronary syndrome. Bangladesh Med J.42(2):6
Safak S, Uslu A.U., Serdal K, Turker T, Soner S, Lutfi A. 2014. Association between mean
platelet volume levels and inflammation in SLE patients presented with arthritis.
African Health Sciences. 14(4)
Sahin A, Yetisgin A, Sahin M, Durmaz Y, Cengiz A. 2016. Can Mean Platelet Volume Be a
Surrogate Marker of Inflammation in Rheumatic Diseases?. West Indian Med J. 65(1):
165
Shin, K.C., Lee, Y.J., Kang, S.W., et al. 2001. Serum Procalcitonin measurement for
detection of intercurrent infection in febrile patients with SLE. Ann Rheum
Dis.60:988-9
Simard, J.F., Costenbader, H. 2011. Epidemiology and Clasification of systemic lupus
th
erythematosus. Dalam: Rheumatology Editor: Hocberg MC, et al. 5 edition.
Philadelphia: Mosby Elsevier. hlm.1223-1246
Simon, L., Gauvin, F., Amre, D.K., Saint-Louis, P., Lacroix, J. 2004. Serum procalcitonin
and C-reactive protein levels as markers of bacterial infection: a systematic review
and meta-analysis. Clin Infect Dis.39(2):206–17
Sherif M, Noor RA, Attia M, Eldeen N. 2019. Changes of Platelet Indices in Patients with
Systemic Lupus Eythematosus and their Correlation with Disease Activity.
Med.J.Cairo Univ. 87 (5):2801 – 2808.
Sit M, Kargi E, Aktas G, Dikbas O, Alcelik A, Savli H. 2014. Mean Platelet Volume should
be Useful Indicator in Diagnosis of Hashimoto’s Thyroiditis. Acta Medica
Mediterranea.30:4
Servet Y, Yildirim A, Gozel N, Uz B, Koca SS., 2016. Hematological Indices May Be Useful
in yhe Diagnosis of Systemic Lupus Erythematosus and in Determining Disease
Activity in Bechet Disease. Med Princ Pract.25:510-516
Suarjana, I.N. 2014. Imunopatogenesis Lupus Eritematosus Sistemik. Dalam: Setiati S,
editor. Buku Ajar Ilmu Penyakit Dalam. Jilid III edisi VI. Jakarta: BP FKUI.
hlm.3331-41
Suntoko, B. 2014. Gambaran Klinik dan Diagnosis Lupus Eritematosus Sistemik. Dalam:
Setiati S, editor. Buku Ajar Ilmu Penyakit Dalam. Jilid III edisi VI. Jakarta: BP FKUI.
hlm.3351.
Tassiulas, I.O., Boumpas, D.T. 2009. Clinical features and treatment of systemic lupus
erythematosus Dalam: Kelly’s Textboox of Rheumatology 8th Ed. Editor: Firestein
GS, Budd RC, Harris ED, Innes IB et al, Elsevier. hlm.1263-1300
Tsokos, G.C. 2011. Mechanisms of Disease Systemic Lupus Erythematosus. N Engl J Med.
365:2110-21
Weening, J.J., D’Agati, V.D., Schwartz, M.M., Seshan, S.V., Alpers, C.E., Appel, G.B., et al.
2004. The classi!ication of glomerulonephritis in systemic lupus erythematosus
revisited. J Am Soc Nephrol.15:241-50
Zhin- H, Chen Y, Zhang L, Sun Y, Huang YL, Wang Q.,et al.2013. Red blood cell
distribution width is potential index to assess the disease activity of systemic lupus
erythematosus. Clinica Chimica Acta. 425:202-205
Yazdany J.2013. Definition and Classification of Lupus and Lupus- Related Disorders In:
Daniel J.Wallace BHH, editor. Dubois’ Lupus Erythematosus and Related
Syndromes. Philadelphia: Elsevier 42(1):145-147
Yavuz S, Ece A. 2014. Mean Platelet volume as an indicator of disease activity in juvenile
SLE. Clinical Rheumatology. 33 (5): 637 - 641
Yuianti Y, Rachmawati B. 2016. RDW, Jumlah Trombosit dan RPR dengan Indeks FIB-4 DI
Hepatitis C. Clinical Pathology and Medical Laboratory. 22(2): 147-150
Yolbas S, Yildirim A, Gozel N, Uz B, Koca SS., 2016. Hematological Indices May Be
Useful in yhe Diagnosis of Systemic Lupus Erythematosus and in Determining
Disease Activity in Bechet Disease. Med Princ Pract.25:510-516
Zhin- H, Chen Y, Zhang L, Sun Y, Huang YL, Wang Q.,et al.2013. Red blood cell
distribution width is potential index to assess the disease activity of systemic lupus
erythematosus. Clinica Chimica Acta. 425:202-205

Abd-Elhafeez, H.A., El-Meghawry, E.S., Omran, T.M., Alsayyad, M.M., Berengy,

M.S. 2017, “Study of Neutrophil Lymphocyte Ratio and Platelet Lymphocyte
Ratio as Inflammatory Markers in Systemic Lupus Erythematosus Egyptian
Patients”, Electronic Journal of Biology, vol. 13, no. 3, hlm.248-252.
Abdulrahman, M.A., Afifia, N., El-Ashryb, M. 2020, “Neutrophil/lymphocyte and
platelet/lymphocyte ratios are useful predictors comparable to serum IL6 for
disease activity and damage in naive and relapsing patients with lupus
nephritis”, The Egyptian Rheumatologist, vol. 42, no.2, hlm. 107-112.
Aktimur, R., Cetinkunar, S., Yildirim, K., Aktimur, S.H., Ugurlucan, M., Ozlem,
N. 2016, “Neutrophil-to-lymphocyte ratio as a diagnostic biomarker for the
diagnosis of acute mesenteric ischemia”, Eur J Trauma Emerg Surg, vol. 42,
hlm. 363-8.
Ali, A., Sayyed, Z., Ameer, M. A., Arif, A. W., Kiran, F., Iftikhar, A., Iftikhar,
W., Ahmad, M. Q., Malik, M. B., Kumar, V., Dass, A., Sami, S. A., Sapna,
F., Waqas, N. 2018, “Systemic Lupus Erythematosus: An Overview of the
Disease Pathology and Its Management”, Cureus, vol. 10, no. 9, hal. e3288.
Aringer, M., Costenbader, K., Daikh, D., Brinks, R., Mosca, M., Ramsey-
Goldman, R., Smolen, J.S., Wofsy, D., Boumpas, D.T., Kamen, D.L., Jayne,
D., Cervera, R., Costedoat-Chalumeau, N., Diamond, B., Gladman, D.D.,
Hahn, B., Hiepe, F., Jacobsen, S., Khanna, D., Lerstrøm, K., Massarotti, E.,
 McCune, J., Ruiz-Irastorza, G., Sanchez-Guerrero, J., Schneider, M.,
Urowitz, M., Bertsias, G., Hoyer, B.F., Leuchten, N., Tani, C.,
Tedeschi ,S.K., Touma, Z., Schmajuk, G., Anic, B., Assan, F., Chan, T.M.,
Clarke, A.E., Crow, M.K., Czirják, L., Doria, A., Graninger, W., Halda-
Kiss, B., Hasni, S., Izmirly, P.M., Jung, M., Kumánovics, G., Mariette, X.,
Padjen, I., Pego-Reigosa, J.M., Romero-Diaz, J., Rúa-Figueroa Fernández,
Í., Seror, R., Stummvoll, G.H., Tanaka, Y., Tektonidou, M.G., Vasconcelos,
C., Vital, E.M., Wallace, D.J., Yavuz, S., Meroni, P.L., Fritzler, M.J.,
Naden, R., Dörner, T., Johnson, S.R. 2019, “2019 European League Against
Rheumatism/American College of Rheumatology Classification Criteria for
Systemic Lupus Erythematosus”, Arthritis Rheumatol, vol. 71, no. 9, hlm.
1400-1412.
Aringer, M., Leuchten, N., Johnson, S.R. 2020, “New Criteria for Lupus”, Current
Rheumatology Reports, vol. 22, no. 18.
Azevedo, P.C., Murphy, G., Isenberg, D.A. 2014, “Pathology of systemic lupus
erythematosus: the challenges ahead”, Methods Mol. Biol, vol 1134, hlm. 1-
16.
Borissoff, J.I., Spronk, H.M., ten Cate H. 2011, “The hemostatic system as a
modulator of atherosclerosis”, N Engl J Med, vol. 364, hlm. 1746–1760.
Bustamante JG, Goyal A, Bansal P, Singhal M. StatPearls [Internet]. StatPearls
Publishing; Treasure Island (FL): Jul 4, 2020. Antiphospholipid Syndrome
(Antiphospholipid Antibody Syndrome, APS, APLS)
Carli, L., Tani, C., Vagnani, S., Signorini, V., Mosca, M. 2015, “Leukopenia,
lymphopenia and neutropenia in systemic lupus erythematosus: Prevalence
and clinical impact. A systematic literature review. Seminars in Arthritis and
Rheumatism” http://dx.doi.org/10.1016/j.semarthrit.2015.05.00
Carter, E.E., Barr, S.G., Clarke, A.E. 2016, “The global burden of SLE:
prevalence, health disparities and socioeconomic impact”, Nat Rev
Rheumatol, vol. 12, hlm. 605e20.
Carter, J.B., Carter, S., Saschenbrecker, S., Goeckeritz, B.E. 2018, “Recognition
and Relevance of Anti-DFS70 Autoantibodies in Routine Antinuclear
Autoantibodies Testing at a Community Hospital”, Front Med (Lausanne),
vol. 5, hal. 88.
Celikbilek, M., Dogan, S., Ozbakır, O., Zararsız, G., Kücük, H., Gürsoy, S.,
Yurci, A., Güven, K., Yücesoy, M. 2013, “Neutrophil-lymphocyte ratio as a
predictor of disease severity in ulcerative colitis”, J Clin Lab Anal, vol 27,
no. 1, hlm. 72-6.
Cojocaru, M., Cojocaru, I. M., Silosi, I., & Vrabie, C. D. 2011, “Manifestations of
systemic lupus erythematosus”, Maedica, vol. 6, no. 4, hlm. 330–336.
Deng, Y., Tsao, B.P. 2014, “Advances in lupus genetics and epigenetics”, Curr
Opin Rheumatol, vol. 26, no. 5, hlm. 482-92.
Feng, J.F., Huang, Y., Chen, Q.X. 2014, “Preoperative platelet lymphocyte – ratio
(PLR) is superior to neutrophil – lymphocyte ratio (NLR) as a predictive
factor in patients with esophageal squamous cell carcinoma”, World J Surg
Oncol, vol. 12, no. 1.
Ferretti, C., & La Cava, A. 2016, “Overview of the Pathogenesis of Systemic
Lupus Erythematosus”, Systemic Lupus Erythematosus, hlm. 55–62.
doi:10.1016/b978-0-12-801917-7.00008-5
Gary, T., Pichler, M., Belaj, K., Hafner, F., Gerger, A., Froehlich, H., Eller, P.,
Rief, P., Hackl, G., Pilger, E., Brodmann, M. 2013, “Platelet-to-lymphocyte
ratio: a novel marker for critical limb ischemia in peripheral arterial
occlusive disease patients”, PLoS One, vol. 8, no. 7, hal. e67688.
Gasparyan, A.Y., Ayvazyan, L., Mukanova, U., Yessirkepov, M., Kitas, G.D. 2019,
“The Platelet-to-Lymphocyte Ratio as an Inflammatory Marker in Rheumatic
Diseases”, Annals of Laboratory Medicine, vol. 39, no. 4, hal. 345.
Gergianaki, I., Bortoluzzi, A., Bertsias, G. 2018, “Update on the epidemiology,
risk factors, and disease outcomes of systemic lupus erythematosus”, Best
Practice & Research Clinical Rheumatology, hlm. 1-18.
Han, B.K., Wysham, K.D., Cain, K.C., Tyden, H., Bengstsson, A.A., Lood, C.
2020, “Neutrophil and lymphocyte counts are associated with different
immunopathological mechanisms in systemic lupus Erythematosus”, Lupus
Science & Medicine, vol. 7, hal. e000382.
Hu, Z.D., Sun, Y., Guo, J., Huang, Y.L., Qin, B.D., Gao, Q., Qin, Q., Deng, A.M.,
Zhong, R.Q. 2014, “Red blood cell distribution width and
neutrophil/lymphocyte ratio are positively correlated with disease activity in
primary Sjögren’s syndrome”, Clin Biochem, vol. 47, hlm. 287–90.
Ismunandar, Syahriani, F., Faridin, H.P., Bakri, S., Kasim, H., Harjianti, T., Katu,
S., Rasyid, H., Seweng, A. 2020, “Neutrophyl Lymphocyte Ratio and
Platelet Lymphocyte Ratio Associated With Disease Activity in Patients
with Systemic Lupus Erythematosus”, European Journal of Molecular and
Clinical Medicine,vol. 7, no. 8, hlm. 978-984.
Izmirly, P.M., Parton, H., Wang, L., McCune, W.J., Lim, S.S., Drenkard, C.,
Feruci, E.D., Dall’Era, M., Gordon, C., Helmick, C.G., Somers, E.C. 2021,
“Prevalence of Systemic Lupus Erythematosus in the United States:
Estimates From a Meta- Analysis of the Centers for Disease Control and
Prevention National Lupus Registries”, Arthritis and Rheumatology, vol. 73,
hlm. 991-996.
Kasjmir, Y.I., Handono, K., Wijaya, L.K., et al. 2014. Diagnosis dan Pengelolaan
Lupus Eritematosus Sistemik. Dalam: Setiati S (ed.). Buku Ajar Ilmu
Penyakit Dalam. Jilid III. Edisi VI. Jakarta: BP FK UI. pp. 3360-3375
Kaya, H., Ertaş, F., İslamoğlu, Y., Kaya, Z., Atılgan, Z.A., Çil, H., Çalışkan, A.,
Aydın, M., Oylumlu, M., Soydinç, M.S. 2014, “Association between
neutrophil to lymphocyte ratio and severity of coronary artery disease”, Clin
Appl Thromb Hemost, vol. 20, hlm. 50-4.
Kuhn, A., Bonsmann, G., Anders, H.J., Herzer, P., Tenbrock, K., Schneider, M.
2015, “The Diagnosis and Treatment of Systemic Lupus Erythematosus”,
Dtsch Arztebl Int, vol 112, no. 25, hlm. 423-432.
Lauddin, E.A., Nurulita, A., Muhadi, D. 2019, “Analisis rasio netrofil limfosit dan
rasio platelet limfosit terhadap penanda gangguan ginjal pada penyakit
systemic lupus erythematosus di RSUP dr. Wahidin Sudirohusodo tahun
2017-2018”, Intisari Sains Medis, vol. 10, no. 1, hlm. 251-255.
Lee, Y. H., Song, G. G. 2017, “Association of Neutrophil to Lymphocyte Ratio,
Platelet to Lymphocyte Ratio, and Mean Platelet Volume with Systemic
Lupus Erythematosus Disease Activity: A Meta-analysis”, Journal of
Rheumatic Diseases, vol. 24, no. 5, hal. 279.
Lehman T, Nuruzzaman F, Taber S. Chapter 8 - Systemic Lupus Erythematosus:
Etiology, Pathogenesis, Clinical Manifestations, and Management. .
Handbook of Systemic Autoimmune Diseases. 2016. Elservier, vol. 11,
2016, hlm. 173-189.
Li, L., Xia, Y., Chen, C., Cheng, P., Peng, C. 2015, “Neutrophil-lymphocyte ratio
in systemic lupus erythematosus disease: a retrospective study”, Int J Clin
Exp Med, vol. 8, no. 7, hlm. 11026-31.
Li, W., Liu, Q., Tang, Y. 2017, “Platelet to lymphocyte ratio in the prediction of
adverse outcomes after acute coronary syndrome: a meta-analysis”, Sci Rep,
vol. 7, no. 40426.
Lim, S.S., Bayakly, A.R., Helmick, C.G., Gordon, C., Easley, K.A., Drenkard, C
2014, “The incidence and prevalence of systemic lupus erythematosus,
2002e2004: the Georgia Lupus Registry”, Arthritis Rheum, vol. 66, hal.
357e68.
Lou, M., Luo, P., Tang, R., Peng, Y., Yu, S., Huang, W., He, L. 2015,
“Relationship between neutrophil-lymphocyte ratio and insulin resistance in
newly diagnosed type 2 diabetes mellitus patients”, BMC Endocr Disord,
vol. 15, no.9.
Ma, L., Zeng, A., Chen, B., Chen, Y., Zhou, R.. 2019, “Neutrophil to lymphocyte
ratio and platelet to lymphocyte ratio in patients with systemic lupus
erythematosus and their correlation with activity: A meta-analysis”,
International Immunopharmacology, vol. 76, hal. 105949.
Martins, E. C., Silveira, L., Viegas, K., Beck, A. D., Fioravantti Júnior, G.,
Cremonese, R. V., & Lora, P. S. 2019, “Neutrophil-lymphocyte ratio in the
early diagnosis of sepsis in an intensive care unit: a case-control study”,
Revista Brasileira de terapia intensiva, vol. 31, no. 1, hlm. 64-70.
Mosca, M., Bombardieri, S. 2005, “Assessing remission in systemic lupus
erythematosus”, Clinical and experimental rheumatology, vol 24, no. 43,
hlm. S100-S104.
Oehadian, A., Suryadinata, H., Dewi, S., Pramudyo, R., Alisjahbana, B. 2013,
“The Role of Neutrophyl Lymphocyte Count Ratio as an Inflammatory
Marker in Systemic Lupus Erythematosus”, Acta Medica Indonesiana - The
Indonesian Journal of Internal Medicine, vol. 45, no. 3, hlm. 170-174.
Petri, M., Orbai, A.M., Alarcón, G.S., Gordon, C., Merrill, J.T., Fortin, P.R., Bruce,
I.N., Isenberg, D., Wallace, D.J., Nived, O., Sturfelt, G., Ramsey-Goldman, R.,
Bae, S.C., Hanly, J.G., Sánchez-Guerrero, J., Clarke, A., Aranow, C., Manzi,
S., Urowitz, M., Gladman, D., Kalunian, K., Costner, M., Werth, V.P., Zoma,
A., Bernatsky, S., Ruiz-Irastorza, G., Khamashta, M.A., Jacobsen, S., Buyon,
J.P., Maddison, P., Dooley, M.A., van Vollenhoven, R.F., Ginzler, E., Stoll, T.,
Peschken, C., Jorizzo, J.L., Callen, J.P., Lim, S.S., Fessler, B.J.,
 Inanc, M., Kamen, D.L., Rahman, A., Steinsson, K., Franks, A.G., Sigler, L.,
Hameed, S., Fang, H., Pham, N., Brey, R., Weisman, M.H., McGwin, G.,
Magder, L.S. 2012, “Derivation and validation of the Systemic Lupus
International Collaborating Clinics classification criteria for systemic
lupus erythematosus”, Arthritis Rheum,vol. 64, no. 8, hlm. 2677-86.
Pisetsky, D.S., 2016, “Anti-DNA antibodies–quintessential biomarkers of SLE”,
Nat. Rev. Rheumatol, vol. 12, no. 2, hlm. 102–110.
Pons-Estel, G.J., Ugarte-Gil, M,F., Alarcón, G.S. 2017, “Epidemiology of systemic
lupus erythematosus”, Expert Rev Clin Immunol, vol. 13, no. 8, hlm. 799-814.
Qu, C. Zhang, J., Zhang, X., Du, J., Su, B, Li, H. 2018. Value of combined
detection of anti-nuclear antibody, anti-double-stranded DNA antibody
and C3, C4 complements in the clinical diagnosis of systemic lupus
erythematosus. Experimental and Therapeutic Medicine, vol. 17, no.2.
Rees, F., Doherty, M., Grainge, M., Davenport, G., Lanyon, P., Zhang, W. 2014,
“The incidence and prevalence of systemic lupus erythematosus in the
UK, 1999–2012”, Ann Rheum Dis, vol. 75, hlm. 136–141.
Rianthavorn, P., Prurapark, P. 2020, “Infections in hospitalized children with
newly diagnosed systemic lupus erythematosus in underresourced
areas”, Lupus, vol. 29, no. 11.
Sen, B.B,. Rifaioglu, E.N., Ekiz, O., Inan, M.U., Sen, T., Sen, N. 2014, “Neutrophil
to lymphocyte ratio as a measure of systemic inflammation in psoriasis”,
Cutan Ocul Toxicol, vol. 33, hlm. 223–7.
Sobhya N, Niazy, M.H., Kamalb, A. 2020, “Lymphopenia in systemic lupus
erythematosus patients: Is it more than a laboratory finding?”, The
Egyptian Rheumatologist, vol. 42, no. 1, hlm. 23-26.
Smirnova, E.V., Krasnova, T.N., Proskurnina, E.V., Mukhin, N.A. 2017, “Rol'
disfunktsii neĭtrofilov v patogeneze sistemnoĭ krasnoĭ volchanki [Role of
neutrophil dysfunction in the pathogenesis of systemic lupus
erythematosus]”, Ter Arkh, vol. 89, no. 12, hlm. 110-113.
Smith, Carolyne K.; Kaplan, Mariana J. 2015, “The role of neutrophils in the
pathogenesis of systemic lupus erythematous”, Current Opinion in
Rheumatology, vol. 27, no. 5, hlm. 448-453.
Solhjoo M, Bansal P, Goyal A, Chauhan K. StatPearls [Internet]. StatPearls
Publishing; Treasure Island (FL): Jul 4, 2020. Drug-Induced Lupus
Erythematosus
Soliman, W.M., Sherif, N.M., Ghanima, I.M., & EL-Badawy, M.A. 2020, “Neutrophil
to Lymphocyte and Platelet to Lymphocyte Ratios in Systemic Lupus
Erythematosus: Relation With Disease Activity and Lupus Nephritis”,
Reumatología Clínica, vol. 16, no. 4, hlm. 255–261.

60
Somers, E.C., Marder,W., Cagnoli, P., Lewis, E.E., DeGuire, P., Gordon, C.,
Helmick, C.G., Wang, L., Wing, J.J., Dhar, J.P., Leisen, J., Shaltis, D.,
McCune, W.J. 2014, "Population-based incidence and prevalence of
systemic lupus erythematosus: the Michigan Lupus Epidemiology and
Surveillance program”, Arthritis Rheumatol, vol. 66, no. 2, hlm. 369-78.
Suppiah, A., Malde, D., Arab, T., Hamed, M., Allgar, V., Smith, A.M., Morris-
Stiff, G. 2013, “The prognostic value of the neutrophillymphocyte ratio
(NLR) in acute pancreatitis: identification of an optimal NLR”, J
Gastrointest Surg, vol. 17, hlm. 675-81.
Suszek, D., Górak, A., Majdan, M. 2020, “Differential approach to peripheral
blood cell ratios in patients with systemic lupus erythematosus and various
manifestations”, Rheumatol Int, vol. 40, hlm. 1625–1629.
Tan, D., Fu, Y., Su, Q., Wang, H. 2016, “Prognostic role of platelet: lymphocyte
ratio in colorectal cancer: a systematic review and meta-analysis”, Medicine
(Baltimore), vol. 85, no. e3837.
Tani, C., D'Aniello, D., Delle Sedie, A., Carli, L., Cagnoni, M., Possemato, N.,
Carbone, M., Della Rossa, A., Riente, L., Baldini, C., Talarico, R., Caramella,
D., Bombardieri, S., Mosca, M. 2013, “Rhupus syndrome: assessment of its
prevalence and its clinical and instrumental characteristics in a prospective
cohort of 103 SLE patients”, Autoimmun Rev, vol. 12, no. 4, hlm. 537–41.
Tedeschi, S.K., Johnson, S.R., Boumpas, D., Daikh, D., Dörner, T., Jayne, D.,
Kamen, D., Lerstrøm, K., Mosca, M., Ramsey-Goldman, R., Sinnette, C.,
Wofsy, D., Smolen, J.S., Naden, R.P., Aringer, M., Costenbader, K.H. 2018,
“Developing and refining new candidate criteria for systemic lupus
erythematosus classification: an international collaboration”, Arthritis Care
Res (Hoboken), vol. 70, no. 4, hlm. 571–81.
Tedeschi, S.K., Johnson, S.R., Boumpas, D.T., Daikh, D., Dörner, T., Diamond,
B., Jacobsen, S., Jayne, D., Kamen, D.L., McCune, W.J., Mosca, M.,
Ramsey-Goldman, R., Ruiz-Irastorza, G., Schneider, M., Urowitz, M.,
Wofsy, D., Smolen, J.S., Naden, R.P., Aringer, M., Costenbader, K.H. 2019,
“Multicriteria decision analysis process to develop new classification
criteria for systemic lupus erythematosus”, Ann Rheum Dis, vol 78, no. 5,
hlm. 634– 40.
Templeton, A.J, Ace, O., McNamara, M,G., Al-Mubarak, M., Vera-Badillo, F.E.,
Hermanns, T., Seruga, B., Ocaña, A., Tannock, I.F., Amir, E. 2014,
“Prognostic role of platelet: lymphocyte ratio in solid tumors: a systematic
review and meta-analysis”, Cancer Epidemiol Biomarkers Prev, vol. 23,
hlm. 1204-12.
Tsokos, G.C., Lo, M.S., Costa Reis, P., Sullivan, K.E. 2016, “New insights into
the immunopathogenesis of systemic lupus erythematosus”, Nat. Rev.
Rheumatol, vol. 12, no. 12, hlm. 716–730.
Turkmen, K., Erdur, F.M., Ozcicek, F., Ozcicek, A., Akbas, E.M., Ozbicer, A.,
Demirtas, L., Turk, S., Tonbul, H.Z. 2013, “Platelet-to-lymphocyte ratio
better predicts inflammation than neutrophil-to- lymphocyte ratio in end-
stage renal disease patients”, Hemodialysis International, vol. 17, hlm. 391–
396.
Uthamalingam, S., Patvardhan, E.A., Subramanian, S., Ahmed, W., Martin, W.,
Daley, M., Capodilupo, R. 2011, “Utility of the neutrophil to lymphocyte
ratio in predicting long-term outcomes in acute decompensated heart
failure”, Am J Cardiol, vol. 107, hlm. 433-8.
Utomo WN. Hubungan antara aktifitas penykit dengab status kesehatan pada
pasien LES (Lupus Eritematosus Sistemik) di RSUP dr. Kariadi, Semarang.
Karya Tulis Ilmiah, Universitas Diponegaro 2012.
Vaillant AAJ, Goyal A, Varacallo M. StatPearls [Internet]. StatPearls Publishing;
Treasure Island (FL): Agustus 10, 2020. Systemic Lupus Erythematosus
(SLE)
Varım, C., Acar, B.A., Uyanık, M.S., Acar, T., Alagoz, N., Nalbant, A., Kaya, T.,
Ergenc, H. 2016, “Association between the neutrophil-to-lymphocyte ratio,
a new marker of systemic inflammation, and restless legs syndrome”,
Singapore Med J, col. 57, no. 9, hlm. 514-516.
Wang, L., Wang, C., Jia, X., Yang, M., Yu, J. 2020, “Relationship between
Neutrophil-to-Lymphocyte Ratio and Systemic Lupus Erythematosus: A
Metaanalysis”, CLINICS, vol. 75, hal. e1450
Wang, Q., Ma, J., Jiang, Z., Ming, L. 2018, “Prognostic value of neutrophil-to-
lymphocyte ratio and platelet-to-lymphocyte ratio in acute pulmonary
embolism: a systematic review and meta-analysis”, Int Angiol, vol. 37, hlm.
4-11.
Washio M, Kiyohara C, Ohta A. (February 13th 2019). Epidemiology of Systemic
Lupus Erythematosus, Lupus - New Advances and Challenges, Sophia
Lionaki, IntechOpen, DOI: 10.5772/intechopen.84146. Available from:
https://www.intechopen.com/books/lupus-new-advances-and-challenges/
epidemiology-of-systemic-lupus-erythematosus
Wichainun R, Kasitanon N, Wangkaew S, Hongsongkiat S, Sukitawut W,
Louthrenoo W. 2013. Sensitivity and specificity of ANA and anti-dsDNA in
the diagnosis of systemic lupus erythematosus: a comparison using control
sera obtained from healthy individuals and patients with multiple medical
problems. Asian Pac J Allergy Immunol, vol. 4, pp. 292-8.
Wu, Y., Chen, Y., Yang, X., Chen, L,, Yang, Y. 2016, “Neutrophil-to-lymphocyte
ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were associated with
disease activity in patients with systemic lupus erythematosus”, Int
Immunopharmacol, vol. 36, hlm. 94-99.
Yenigun, A. 2015, “The efficacy of tonsillectomy in chronic tonsillitis patients as
demonstrated by the neutrophil-to-lymphocyte ratio”, J Laryngol Otol, vol.
129, hlm. 386-91.
Yu, H., Jiang, L., Yao, L., Gan, C., Han, X., Liu, R., & Su, N. 2018, “Predictive
value of the neutrophil-to-lymphocyte ratio and hemoglobin insystemic
lupus erythematosus”, Experimental and therapeutic medicine, vol. 16, no.
2, hlm. 1547–1553.
Zhan, H., Ma, J.Y., Jian, Q.C. 2018, “Prognostic significance of pretreatment
neutrophil-to-lymphocyte ratio in melanoma patients: A meta-analysis”,
Clinica Chimica Acta, vol. 484, hlm. 136-140.
Zian, Z., Maamar, M., Aouni, M., Barakat, A., Nourouti, N.G., Aouad, R., Arji, N,
Mechita, M.B. 2018, “Immunological and Clinical Characteristics of
Systemic Lupus Erythematosus: A Series from Morocco”, BioMed Research
International, https://doi.org/10.1155/2018/3139404.
Alamoudi, O.S.B., Attar, S.M. 2015. Pulmonary Manifestations in Systemic

Lupus Erythematosus :Association with disease activity. Respirology: 20,

474–480.

Alza, YS, Motta, JZN, Rivero, JEF & Pineda, CLF 2018, ‗Systemic Lupus

Erythematosus, Gender Differences in Colombian Patients‘, International

League of Associations for Rheumatology (ILAR), dilihat 20 Maret 2019, <

https://doi.org/10.1007/s10067-018-4161-8>

Arsita, E. 2014. Peran Infeksi Sebagai Prediktor Mortalitas Pada Pasien Lupus

Eritematosus Sistemik yang Dirawat Inap. Tesis Program Pendidikan Dokter

Spesialis Penyakit Dalam Universitas Indonesia.

Ayudiatama, R.S. 2012. Uji Diagnostik Prokalsitonin Dibanding Kultur Darah

Sebagai Baku Emas Untuk Diagnosis Sepsis Bakteriali di RSUP dr.Kariadi.

Skripsi Program Sarjana Kedokteran Universitas Diponegoro.

Bador, KM, Intan, S, Hussin, S & Gafor, AHA 2012, ‗Serum procalcitonin has

negative predictive value for bacterial infection in active systemic lupus

erythematosus‘, vol. 21, hh. 1172-1177.

Bashal, F. 2013. Hematological Disorders in Patients with Systemic Lupus

Erythematosus. The Open Rheumatology Journal: 7;87-95.

Barbhaiya, M., Costenbader, K.H. 2016. Environmental Exposures and the

Development of Systemic Lupus Erythematosus. Curr Opin Rheumatol;

28(5): 497–505.

Barber, C, Gold, WL & Fortin, PR 2011, ‗Infections in The Lupus Patient:

Perspectives on Prevention‘, Current Opinion in Rheumatology, Vol. 23, hh.

358-365.

Becker, KL, Snider, R & Nylen, ES 2010, ‗Procalcitonin In Sepsis And Systemic

Inflammation: A Harmful Biomarker And A Therapeutic Target‘, British

Journal of Pharmacology, vol. 159, hh. 253–264.

Bello, GA et al ., 2016, ‗ Development And Validation of A Simple Lupus

Severity Index Using ACR Criteria for Classification of SLE‘, Lupus

Science & Medicine, vol. 3, no. e000136, <doi:10.1136/lupus-2015-

000136>.

Bertsias, G., Cervera, R., Boumpas, D.T. 2012. Systemic Lupus

Erythematosus :Pathogenesis and Clinical Features, EULAR Textbook on

Rheumatic Disease. Switzerland. hlm. 476-505.

Brinks et al., 2016, ‗Age-specific and sex-specific incidence of systemic lupus

erythematosus: an estimate from cross-sectional claims data of 2.3 million

people in the German statutory health insurance 2002‘, Lupus Science &

Medicine, vol. 3, no. e000181. <doi:10.1136/lupus-2016-000181>Carter, E.,

Barr, S.G., Clarke, A.E. 2016. The Global Burden of SLE: Prevalence,
 Health Disparities and Sosioeconomic Impact. Nature Review

Rheumatology: 12; 605-620.

C.A. Scirè, L. Cavagna, 2006. Diagnostic value of procalcitonin measurement in

febrile patients with systemic autoimmune diseases. Clinical and

Experimental Rheumatology . hlm.123 – 128

Ceccarelli, F., Perricone, C., Borgiani, P. 2015. Genetic Factors in Systemic

Lupus Erythematosus: Contribution to Disease Phenotype. Hindawi

Publishing Corporation Journal of Immunology Research.

Cohen-Solal, JFG., Jeganathan V., Hill L. 2008. Hormonal regulation of B-cell

function and systemic lupus erythematosus. Lupus: 17, 528–532.

Cozzani, E., Drosera, M., Gasparini, G. et al. Serology of Lupus Erythematosus:

Correlation between Immunopathological Features and Clinical Aspects.

Hindawi Publishing Corporation Autoimmune Diseases.

Dornbusch, HJ et al., 2008, ‗Non-Infectious Causes of Elevated Procalcitonin

And C-Reactive Protein Serum Levels in Pediatric Patients with

Hematologic and Oncologic Disorders‘, Support Care Cancer, vol. 16, hh.

1035-1040.

Era, MD & Chakravaty, EF 2011, ‗Treatment of Mild, Moderate, and Severe

Lupus Erythematosus: Focus on New therapies‘, Current Rheumatology

Reports, vol. 13, no. 4, hh. 308–316.

Fabio E. Ospina, Alex Echeverri, et al .2017. Distinguishing infections vs flares in

patients with systemic lupus erythematosus Rheumatology, Volume 56,

Issue suppl_1, April 2017, Pages i46–i54

Garcia, G.D., Galarza-Delgado, D.A.G., Coulunga-Pedarza, I. et al. 2016. Mean

Platelet Volume Is Decrease in Adult With Active Lupus Disease. Rev Bras

Rheumatol:56(6): 104-108.

Gottschalk, T.A., Tsantikos, E., Hibbs, M.L. 2015. Patogenic Inflmmation and Its

Terapeutic Targeting in Systemiv Lupus Erythematosus. Front Immunol: (6)

550.
Grossman, JM 2009, ‗Lupus arthritis‘, Best Practice & Research Clinical

Rheumatology, vol. 23, hh. 495–506.

Guavera et al., 2015, ‗Risk Factors for Complicated Pneumonia in Systemic

Lupus Erythematosus (SLE)’, ACR/ARHP Arthritis Rheumatology, vol. 67,

no. 10, < https://acrabstracts.org/abstract/risk-factors-for-complicated-

pneumonia-in-systemiclupus-erythematosus-sle/>

Hoffman, IEA, Peene, I, Meheus, L et al., 2004,‘ Specific Antinuclear Antibodies

Are Associated With Clinical Features In Systemic Lupus Erythematosus‘,

Annals of Rheumatic Disease, vol. 63, hh. 1155-1158.

Ho, WL 2009, ‗Pct May Be Potential Biomarker For Distinguishing Bacterial

Infection From Disease Activity In Febrile Patients With Sle‘, Formosan

Journal of Rheumatology, vol. 23, hh. 52-58.

Hyuck Lee, et al. 2013. Procalcitonin as a biomarker of infectious diseases.

Korean J Intern Med. 2013 May; 28(3): 285–291

Isbagio, H., Albar, Z., Kasjmir, I.H., Setiyohadi, B. 2012. Lupus Eritematosus

sistemik. Dalam: Sudoyo AW. Buku Ajar Ilmu Penyakit Dalam. Jilid III

edisi V. Jakarta: BP FKUI. hlm. 2565-2579.

Irastorzal, G.R., Espinosa, G., Frutos, M.A. 2012. Diagnosis and treatment of

lupus nephritis. Nefrologia;32(1):1-35.

Irina Buhaescu, 2010. Serum Procalcitonin in Systemic Autoimmune Diseases—

Where Are We Now?. Seminars in Arthritis and Rheumatism, 40(2), 176–

183. doi:10.1016/j.semarthrit.2009.10.004

J Torres-Ruiz, A Barrera-Vargas, et al .2018. Microbiological and immunological

profile of patients with severe lupus flares related to bloodstream infections:

 a retrospective cohort study.journals sagepub. Volume: 27 issue: 2, page(s):

312-318

Jung, JY & Suh, CH 2017, ‗Infection in Systemic Lupus Erythematosus,

Similarities, and Differences with Lupus Flare‘, The Korean Journal of

Internal Medicine, vol. 32, no. 3, hh. 429-438.

Kasama, T., Maeoka, A., Oguro, N. 2016. Clinical Features of Neuropsychiatric

Syndromes in Systemic Lupus Erythematosus and Other Connective Tissue

Diseases. Clinical Medicine Insight Arthritis and Musculoskeletal

Disorders: (9): 1-8

Kupczyk, M , Antczak, A, Kuna, P & Gorski , P 2008, ‗Life Threatening

Pneumonia in A Lupus Patient: A Case Report‘, Formosan Journal of

Rheumatology

Lanoix, JP et al., 2011, ‗Serum Procalcitonin Does Not Differentiate Between

Infection and Disease Flare in Patients With Systemic Lupus

Erythematosus‘, Lupus, vol. 20, hh. 125-130. Cases Journal BioMed

Central, vol. 1 , no. 70.

Lee, B 2013, ‗Procalcitonin as A Biomarker of Infectious Diseases‘, The Korean

Journal of Internal Medicine, vol. 28, no. 3, hh. 285-291.

Liossis, N.C., Tsokos G.C., et al. 2010. Molecular Aspects in the Pathogenesis of

Human Systemic Lupus Erythematosus. Archivum Immunologiae et

Therapiae Experimentalis. 4:8, 11–19

Marwanta, S. 2012. Pengaruh N-Asetil Sistein Oral Terhadap Penurunan Kadar

TNF-α dan Proklasitonin pada Pasien Penyakit Ginjal Kronis Stadium V

 yang Menjalani CAPD di RSUP Dr.Moewardi Surakarta. Tesis Program

Pasca Sarjana Universitas Sebelas Maret Surakarta.

Meisner, M. 2010. Procalcitonin – Biochemistry and Clinical Diagnosis 1st

Edition. Bremen. UNI- MED Verlag AG. Hlm 9-79.

Ming Jin, PhD, Adil I. Khan, PhD. 2010. Procalcitonin: Uses in the Clinical

Laboratory for the Diagnosis of Sepsis. labmedicine. March 2010 .Volume

41 Number 3 .

Mocarzel, L.O.C., Lanzieri, P.,G., Montes, R.A. 2015. Systemic Lupus

Erythematosus: Review of Cardiovascular Aspects. Internacional Journal of

Cardiovascular Sciences; 28(3):251-261

Muscal, M., Brey, R.B. 2010. Neurological Manifestations of Systemic Lupus

Erythematosus in Children and Adults. Neurol Clin; 28(1): 61–73.

Ninghtingale, AL, Davidson, JE, Molta, TC, Kan, HJ & McHugh, NJ 2017,

‗Presentation Of SLE In UK Primary Care Using The Clinical Practice

Research Datalink‘, Lupus Science and Medicine, vol.4, hh.1-10.

Patrick, J, Marpaung, B & Ginting, Y 2019, ‗Differences of Serum Procalcitonin

Levels Between Bacterial Infection and Flare in Systemic Lupus

Erythematosus Patients‘, IOP Conference Series: Earth and Environmental

Science, vol. 12, <doi :10.1088/1755-1315/125/1/012157>.

Platinga, L, Lim, SS, Bowling, CB & Drenkard, C 2016, ‗Association Of Age

With Health-Related Quality Of Life In A Cohort Of Patients With Systemic

Lupus Erythematosus: The Georgians Organized Against Lupus Study‘,

Lupus Science & Medicine, vol. 3, no. e00016, hh. 1-9.

Pusdatin RI, 2017, Situasi Lupus di Indonesia, Departemen Kesehatan RI,

<http://www.depkes.go.id/resources/download/pusdatin/infodatin/Infodatin-

Lupus-2017.pdf>.

Pons-Estel, G.J., Alarćon, G.S., Scofield, L., Reinlib, L., Cooper, G.S. 2010.

Understanding the epidemiology and progression of systemic lupus

erythematosus. Semin Arthritis Rheum.39:257-68.

Ralp, B 2016, ‗Age-specific and sex-specific incidence of systemic lupus

erythematosus: an estimate from cross-sectional claims data of 2.3 million

people in the German statutory health insurance 2002‘, BMJ

Raza,MA & Khan, MIH 2012, ‗Systemic Lupus Erythematosus: Disease

Manifestations In Patients from Central Punjab (Pakistan)‘, International

Journal of Clinical Rheumatology, vol. 7, no. 6, hh. 607-614.

Rees, F., Doherty, M., Grainge, M., et al. 2014. The incidence and prevalence of

systemic lupus erythematosus in the UK, 1999–2012.Ann Rheum Dis ;0:1–

Rizky Ayu Fandika Asih, Dyah Mahendrasari Sukendra. 2016. Hubungan

Keparahan Penyakit, Aktivitas, dan Kualitas Tidur Terhadap Kelelahan

Pasien Systemic Lupus Erythematosus. Unnes Journal of Public Health.

UJPH 5 (3) (2016)

Roussou, E. 2013. Stress as a Trigger of Disease Flares in SLE. Rheumatol Int;

33(5): 1367- 1370.

Saleh, A.M. 2013. Penilaian Aktivitas Penyakit Lupus Eritematosus Sistemik

dengan Skor SLEDAI di Departemen Ilmu Kesehatan Anak RSCM. Tesis

Program Pendidikan Dokter Spesialis Anak Universitas Indonesia.

Salehabadi, H.S., Bashiri, H., Majelan, N.N. 2017. Prognostic Factor in Lupus

Nephritis in an Iranian Population. Reumatology Research Journal:2(1); 17-

23.

Schuetz, P., Albrich, E., Mueller, B. 2011. Procalcitonin for diagnosis of infection and

guide to antibiotic decisions : past, present and future. MBC Medicine.9:107

Shin, K.C., Lee, Y.J., Kang, S.W., et al. 2001. Serum Procalcitonin measurement

for detection of intercurrent infection in febrile patients with SLE. Ann

Rheum Dis.60:988-999.

Serio, H, Arnaud, L, Mathian, A, Hausfater, P & Amoura, Z 2014, ‗Can

Procalcitonin be Used to Distinguish Between Disease Flare and infection in

patients with systemic lupus erythematosus: a systematic literature review ‘,

Clinical Rheumatology, vol. 33, no. 1, hh. 1209-1215.

Skare, TL, Dagostini, JS, Zanardi, PI & Nisihara, RM 2016, ‗Infections and

Systemic Lupus Erythematosus, Einsteim, vol. 14, no. 1, hh. 47-51.

Strand, V et al., 2014, ‗A Real-World Characterization of US Patients with

―Moderate-to-Severe‖ Systemic Lupus Erythematosus‘, Epidemiology and

Public Health (ACR): Rheumatoid Arthritis and Systemic Lupus

Erythematosus Outcomes, <https://acrabstracts.org/abstract/a-real-world-

characterization-of-us-patients-with-moderate-to-severe-systemic-lupus-

erythematosus/>.

Simard, J.F., Costenbader, H. 2011. Epidemiology and Clasification of systemic

th
lupus erythematosus. Dalam: Rheumatology Editor: Hocberg MC, et al. 5

edition. Philadelphia: Mosby Elsevier. hlm.1223-1246

Suarjana, I.N. 2014. Imunopatogenesis Lupus Eritematosus Sistemik. Dalam:

Setiati S, editor. Buku Ajar Ilmu Penyakit Dalam. Jilid III edisi VI. Jakarta:

BP FKUI. hlm.3331-41

Sutrisno, R.N., Rahmadi, A.R., Novita, N., et. Al. 2017. Most Frequent

Musculoskeletal Manifestation of Systemic Lupus Erythematosus Patients in

Dr. Hasan Sadikin General Hospital Bandung. Indonesian Journal of

Rheumatology; Vol (9)2; 13-17.

Tian, X.P., Zhang, X. 2010. Gastrointestinal involvement in systemic lupus

erythematosus: Insight into pathogenesis, diagnosis and treatment. World J

Gastroenterol; 16(24): 2971-2977

Uva, L., Miguel, D., Pinheiro C. 2012. Cutaneous Manifestations of Systemic

Lupus Erythematosus. Hindawi Publishing Corporation Autoimmune

Diseases.

Vibeke Strand , Jennifer Johnson , Carl Vandeloo, et al. 2014. A Real-World

Characterization of US Patients with ―Moderate-to-Severe‖ Systemic

Lupus Erythematosus. 2014 ACR/ARHP Annual Meeting. ABSTRACT

NUMBER: 1077

Wijaya, C., Bahrun U. 2017. The Role of Antinuclear Antibody (ANA) Profile in

Diagnosis of Systemic Lupus Erythematosus. Adv Cytol Pathol; 2(5): 133-

134.

Wlika, AE et al., 1997, ‗Assessment Of Systemic Lupus Erythematosus Disease

Activity By Medical Record Review Compared With Direct Standardized

Evaluation‘, Arthritis & Rheumatism, vol. 40, no. 1, hh. 57-61.

Yoshiya Tanaka1 | Akiko Mizukami2 | Akihiro Kobayash. Et al. 2018. Disease

severity and economic burden in Japanese patients with systemic lupus

erythematosus: A retrospective, observational study. Int J Rheum Dis.

2018;21:1609–1618.

Zian, Z 2018, ‗Immunological and Clinical Characteristic of Systemic Lupus

Erythematosus : A Series from Moroko‘, Biomed Research International,

vol. 20, hh 1-5.